We evaluated the ability of both static electric and static magnetic fields to enhance the in vivo action of a chemotherapeutic agent, adriamycin, against transplanted mammary tumors in mice. Female B6C3F1 mice with transplanted mammary adenocarcinoma were divided into four randomized groups and injected with 10 mg/kg adriamycin on day 7 of the study. Three of the groups were then exposed to nonuniform static electric or static magnetic fields. The resulting tumor regression in each group was measured four times during the remaining 13 days of the 20 day study. Two-sided statistical tests revealed all of the static field exposed groups achieved significantly greater (P </=.05) tumor regression than the group treated with adriamycin only, with P-values in a range as low as. 0001. There is an almost universal need in disease treatment to increase the efficacy and delivery of bioactive agents against target cells. The technology demonstrated here may result in improved use of therapeutic materials ranging from drugs to genetic agents. In addition, our findings point to possible hazards from the in vivo enhancing action of static fields on administered or environmentally encountered chemicals.
Copyright 2000 Wiley-Liss, Inc.